Delix Therapeutics

Delix Therapeutics is a clinical-stage neuroscience company based in the Boston area that develops neuroplastogens: orally available, easily manufactured small molecules inspired by psychedelics and engineered to promote structural and functional neural repair without hallucinatory effects. Led by CEO Mark Rus, the company targets neuropsychiatric and neurodegenerative disorders, with lead asset zalsupindole in development for major depressive disorder ahead of a planned Phase IIb proof-of-concept trial.

  • Biotechnology
  • Clinical Trials
  • Mental Health
  • Neuroscience
  • Pharmaceuticals
  • Healthcare & Life Sciences

1

Round

1

Industry

5

Tags

Nov 9, 2026

Latest raise

Funding activity · 1 round

Raise timeline

  1. Nov 9, 2026

    $100M

    Series C+

    Led by Johnson & Johnson Innovation – JJDC, Inc.

    • Vestal Point Capital
    • Johnson & Johnson Innovation – JJDC, Inc.
    • ARTIS Ventures
    • Hamilton Square Partners Management LP
    • UC Investments
    • SV Health Investors’ Dementia Discovery Fund
    • YK Bioventures
    • RA Capital
    • Dolby Family Ventures
    • Adage Capital Management
    • OMX Ventures
    • Bail Capital

    Article coming soon.

Pricing

Research Delix Therapeutics — then scale the playbook

Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.

Enterprise

Custom pricing for unlimited scale. Let's talk.

Contact sales

Growth plan

For individuals and small teams getting started with AI buyer intelligence.

$149

/month

Features

  • Access to core AI adoption signals
  • 3–5 curated slices per week
  • 30–60 companies / week
  • AI Adoption Score
  • Deal-ready insights (why + pitch angle)
  • Basic filters (recency, slice, score)
  • CSV export
Most popular

Pro plan

For outbound teams and agencies that need more coverage and faster signal cadence.

$249

/month

Features

  • Everything in Growth, plus:
  • Full access to all slices
  • 60–120 companies / week
  • Higher-frequency signal updates
  • Priority / early signals (before Growth)
  • Advanced filters (industry, size, use case)
  • Deeper company insights
  • Faster export + bulk workflows

Act on this raise

See if Delix Therapeutics is moving on AI

Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.

© 2026 VeilStrat. All rights reserved.All systems operational